Eidos Therapeutics Inc (EIDX) Insider Sells $115,550.00 in Stock
Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $23.11, for a total transaction of $115,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Eidos Therapeutics stock opened at $23.58 on Friday. The stock has a market capitalization of $859.22 million and a P/E ratio of -12.68. Eidos Therapeutics Inc has a 1 year low of $8.89 and a 1 year high of $25.55.
Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01). On average, analysts anticipate that Eidos Therapeutics Inc will post -1.3 earnings per share for the current year.
Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. BTIG Research assumed coverage on shares of Eidos Therapeutics in a report on Wednesday. They issued a “buy” rating and a $38.00 price objective for the company. JPMorgan Chase & Co. upgraded shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, February 27th. Finally, BMO Capital Markets assumed coverage on shares of Eidos Therapeutics in a report on Friday, February 22nd. They issued an “outperform” rating and a $28.00 price objective for the company. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Eidos Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $28.57.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
See Also: What are earnings reports?
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.